Retrospective study of real-world outcomes with Molecular Tumor Board recommended treatments

The Molecular Tumor Board (MTB) is an important tool for the selection of molecular targeted agents, but its clinical utility is not comfirmed in real-world practice. A retrospective study at the Isituto Nazionale dei Tumor (Milan, Italy) compared real-world outcomes of patients treated according to MTB recommendations (group A), patients eligible for such treatment but receiving other treatments (group B), or patients without a MTB recommendation (group C). Among 1270 patients with metastatic disease, real-world overall survival was not reached in group A, was 17.7 months in group B (versus A: HR 1.76; p=0.002), and was 20.5 months in group C (versus A: HR 1.42; p=0.035). The authors conclude that efforts should be pursued to offer MTB-recommended therapies.